Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction Clinical research trials and A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction. A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction clinical trial. Human subjects frequently get the finest healthcare available for their A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction



A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction

For Condition: Kidney Diseases
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: High dose methotrexate with leucovorin rescue has demonstrated activity in numerous malignancies. Although high dose methotrexate is generally well tolerated, unpredictable life-threatening toxicity can occur. For patients who have markedly delayed clearance of methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited efficacy. Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal glutamate residue. Carboxypeptidase-G2 could be used to rescue patients with renal dysfunction and delayed methotrexate excretion, as it provides an alternative to renal clearance as a route of elimination.
Details: High dose methotrexate with leucovorin rescue has demonstrated activity in numerous malignancies. Although high dose methotrexate is generally well tolerated, unpredictable life-threatening toxicity can occur. For patients who have markedly delayed clearance of methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited efficacy. Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal glutamate residue. Carboxypeptidase-G2 could be used to rescue patients with renal dysfunction and delayed methotrexate excretion, as it provides an alternative to renal clearance as a route of elimination.
Eligibility:
Study Type:
  Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients of any age at risk for life-threatening toxicity following MTX administration secondary to delayed drug excretion as defined by: Plasma MTX concentration at least 10 micromoles/liter more than 42 hours after the start of the MTX infusion; OR Creatinine at least 1.5 times the upper limit of normal or creatinine clearance less than 60 ml/sqm/min and delayed MTX excretion documented by plasma MTX concentration measurements (at least 2 standard deviations above the mean) at least 12 hours following MTX administration.
Total Enrollment: 10

Location and Contact Information:

National Cancer Institute (NCI)
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:
  920134;  92-C-0134
Study Start Date: March 28, 1992
Record last reviewed: February 1, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001298

Other Kidney Diseases Studies:
1. Dynamic Aspects of Amino Acid Metabolism

2. Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

3. Look AHEAD: Action for Health in Diabetes

4. Endolymphatic Sac Tumors in a Population of Patients with von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients with Early Stage Endolymphatic Sac Tumors

5. Omega-3 Fatty Acids that Affect the Immune System in Kidney Transplant Patients

Related Studies:

Other Kidney Diseases Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients with Methotrexate Toxicity and Renal Dysfunction

Modify your Search

  Other Kidney Diseases Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103